key: cord-0283742-cubdgssy authors: Cao, Liu; Li, Yingjun; Yang, Sidi; Li, Guanguan; Zhou, Qifan; Sun, Jing; Xu, Tiefeng; Yang, Yujian; Zhu, Tiaozhen; Huang, Siyao; Ji, Yanxi; Cong, Feng; Luo, Yinzhu; Zhu, Yujun; Luan, Hemi; Zhang, Huan; Chen, Jingdiao; Liu, Xue; Wang, Ping; Yu, Yang; Xing, Fan; Ke, Bixia; Zheng, Huanying; Deng, Xiaoling; Zhang, Wenyong; Li, Chun-Mei; Zhang, Yu; Zhao, Jincun; Zhang, Xumu; Guo, Deyin title: The adenosine analogue prodrug ATV006 is orally bioavailable and has potent preclinical efficacy against SARS-CoV-2 and its variants date: 2021-10-14 journal: bioRxiv DOI: 10.1101/2021.10.13.463130 sha: d2c51dfcbaf487958d861beeffb73ca3ec8b3bb1 doc_id: 283742 cord_uid: cubdgssy Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the COVID-19 pandemic, is rapidly evolving. Due to the limited efficacy of vaccination in prevention of SARS-CoV-2 transmission and continuous emergence of variants of concern (VOC), including the currently most prevalent Delta variant, orally bioavailable and broadly efficacious antiviral drugs are urgently needed. Previously we showed that adenosine analogue 69-0 (also known as GS-441524), possesses potent anti-SARS-CoV-2 activity. Herein, we report that esterification of the 5’-hydroxyl moieties of 69-0 markedly improved the antiviral potency. The 5’-hydroxyl-isobutyryl prodrug, ATV006, showed excellent oral bioavailability in rats and cynomolgus monkeys and potent antiviral efficacy against different VOCs of SARS-CoV-2 in cell culture and three mouse models. Oral administration of ATV006 significantly reduced viral loads, alleviated lung damage and rescued mice from death in the K18-hACE2 mouse model challenged with the Delta variant. Moreover, ATV006 showed broad antiviral efficacy against different mammal-infecting coronaviruses. These indicate that ATV006 represents a promising oral drug candidate against SARS-CoV-2 VOCs and other coronaviruses. The outbreak of COVID-19 pandemic, caused by SARS-CoV-2, has been continuing 54 for over one year and has resulted in over 228 million confirmed infections and over 4 55 million reported deaths worldwide as of 20 September 2021 (WHO 2021b). SARS-56 CoV-2 is a positive-sense, single-stranded RNA virus belonging to the genus ATV006 (250 mg/kg) group having the strongest potency with reduction of viral RNA 247 for more than 10,000 times in the lung (Fig 5D) . 248 Histopathological analysis and observation were performed with the lungs of the 249 mice infected with SARS-CoV-2 at 3 dpi. The vehicle-treated mice showed multiple 250 injuries, including inflammatory cell infiltration ranging from the trachea, peri-alveolar 251 space, to the interstitium whereas ATV006-treated animals had markedly alleviated 252 symptoms in the lungs (Fig 5E and 5F ). Compared with the ATV006 treatment group, 253 the spleen of the mice in the control group was significantly enlarged, and the white 254 pulp was atrophied to varying degrees (Fig 5G and 5H ). Furthermore, ATV006 255 markedly reduced the production of inflammatory cytokines and chemokines in the 256 lung tissues (Fig 5I) . TGEV and SADS-CoV, and the EC50 was 1.040 μM, 0.186 μM, 1.040 μM, 3.045 μM 282 and 2.490 μM, respectively, in cell culture models (Fig 6B-6F ). These results indicate 283 that ATV006 has a broad-spectrum anti-coronavirus efficacy. 284 We further evaluated the anti-coronavirus activity of ATV006 in MHV infection 285 mouse model. The Balb/c mice were inoculated intranasally with 1 x 10 6 PFU per 286 mouse of MHV-A59, and treated with vehicle (control, n=5) or ATV006 (500, 250, 287 100, 50 mg/kg, IG, twice daily, n=5), starting at 3 hours prior to virus inoculation and 288 continuing until 2 days post-infection ( Fig 7A) . We found that ATV006 treatments at 289 different dosages could prevent the weight loss of the mice (Fig 7B) . At 2 dpi, we 290 measured the viral gRNA and sgRNA copy number and virus titer in mouse lung and 291 liver ( Fig S4 and Fig 7) . It was found that the treatments of high dosages of ATV006 292 (250, 500 mg/kg) could effectively inhibit virus replication both in the lung and liver, 293 and the 500 mg/kg group had 99% inhibition of virus replication in the lung and liver 294 ( Fig 7C-7F ) while the treatment of low dosages of ATV006 (50, 100 mg/kg) 295 significantly inhibited viral replication in the liver, but not significantly in the lung ( Fig 296 7C-7F ). Histopathological analysis demonstrated that the vehicle-treated mice showed 297 inflammatory cell infiltration, whereas ATV006 (500 mg/kg)-treated mice had 298 alleviated symptoms in the lungs at 2 dpi ( Fig 7G) . In addition, ATV006 significantly 299 reduced the production of inflammatory cytokines and chemokines, such as IL-6, IL-1β and IFN-γ ( Fig 7H) . Due to the suppression of virus replication, IFN-β and ISGs 301 (CXCL10) also significantly decreased (Fig 7H) . 302 We next explored the lowest oral dosages of ATV006 that could protect MHV-A59-303 infected mice from death and weight loss. As shown in Figure S5 , ATV006 could 304 prevent mouse death and weight loss of mice at dosages of 5-50 mg/kg while the mouse 305 treated with 2 mg/kg of ATV006 began to die 4 days post infection (dpi) and all mice 306 died till 10 dpi. In comparison, the mice of the control group all died at 8 dpi and even 307 the treatment with 2 mg/kg ATV006 prolonged the survival time and reduced the viral 308 load in the liver by about six times (Fig S5B-S5D ). IP administration of remdesivir (20 309 mg/kg) and IG administration of 69-0 (50 mg/kg) could also prevent death of the MHV-310 infected mice ( Fig. S5 ) but the body weight of the mice was reduced in comparison 311 with the mice treated with ATV006. 312 MHV mainly infects the liver of mouse and causes hepatitis. Therefore, we also 313 performed intrahepatic (IH) inoculation to directly observe whether ATV006 had the 314 effect of inhibiting virus replication in the liver and alleviating the symptoms of 315 hepatitis ( Fig S6A) . Intriguingly, compared with the vehicle group, mice treated with 316 the lowest concentration (2 mg/kg) had a 100-fold reduction in virus replication by 317 measurement of the viral RNA load by qPCR, or the virus titer by plaque assay (Fig 318 S6B , S6C and S6D). The serum ALT and AST values of ATV006-treated mouse were 319 significantly lower than that of the control group (Fig S6E and S6F ). The results of 320 histopathological analysis also showed that after ATV006 treatment, the inflammatory 321 cell infiltration in the liver was significantly reduced (Fig S6G) . ATV006 could reduce 322 the production of various inflammatory cytokines ( Fig S6H) . The above results 323 demonstrate that ATV006 could also inhibit the replication of MHV-A59 in both the 324 lung and liver in the mouse model and prevent the death of MHV-infected mice, 325 indicating that ATV006 has a broad anti-coronavirus activity. sites are 100% conserved ( Fig S7) . Therefore, we speculate that the increased 386 sensitivity of Delta to ATV006 may be related to its high replication rate but not to the 387 mutations in RdRp. The detailed mechanism needs to be further investigated in the 388 future work. The analysis of 5,600 SARS-CoV-2 genomes also indicated that the 389 adenosine analog, the parent nucleoside of remdesivir, does not seem to exert high 390 selective pressure (Mari et al. 2021 ), suggesting that ATV006 and similar adenosine 391 analogs have low risk to induce escape mutation and drug resistance. 392 The RdRp-encoding nsp12 is the most conserved protein in the coronaviruses. The demonstrated that ATV006 has potent and broad efficacy against SARS-CoV-2 and its 405 variants of concern as well as other coronaviruses, thus representing a promising orally 406 available drug candidate for the treatment for COVID-19 and emerging coronavirus 407 diseases in the future. The preparation of novel compounds, 1 H NMR, 13 C NMR, HRMS analysis and 411 replaced with fresh DMEM medium, followed by adding each compound (described 448 in Table 1) Table S2 . qPCR primers are listed in Table S3 . Table S2 . qPCR primers are listed in Table S3 . Table S3 . 492 To investigate the effect of drugs on cell viability, Vero E6 cells were seeded in Male SD rats (180-220 g, N = 3) were fasted for 12 h before drug administration. 501 ATV006 was administered intravenously at 4 mg/kg or intragastrically at 20 mg/kg. Three male cynomolgus monkeys (2 to 5 years of age, weighing 3 to 5 kg) were 512 used were orally received AVT006 of 10 mg/kg on day 1. After administration, the 513 blood samples for plasma were collected from a jugular vein into anticoagulant 514 EDTA -K2 tubes at 0.083, 0.25, 0.5, 1, 2, 4, 8, 24 and 48 h. After a 3-day washout 515 period, each animal was administered intravenously with ATV006 at a dose of 5 516 mg/kg, followed by bold collection from the jugular vein at the specified time points. 517 All samples were centrifuged under 4000 rpm/min for 10 min at 4 ℃ and the plasma 518 (supernatants) were collected and stored at -65℃ for future analysis. The 519 concentration of analytes in each sample were analyzed by LC/MS/MS. 520 Five C57BL/6 mice were fasted for 12-16 h before administered orally with a 522 single dose of 100 mg/kg ATV006. After 1 h of dosing, 0.5 mL of the blood sample 523 was taken from heart. Liver, kidney, lung, brain tissues were harvested. The blood 524 sample was processed to the same method as in the rat PK studies. Tissue samples 525 were homogenized and extracted with 70% methanol, after centrifuge under 4000 rpm 526 for 10min, the supernatants were transfer to a clean tube and the concentration of 527 analytes in each sample were analyzed by LC/MS/MS. 528 The experiments were performed as previously described (Sun et al. 2020a ). Mice 530 were lightly anesthetized with isoflurane and transduced intranasally with 2.5 × 10 8 531 FFU of Ad5-ACE2 in 75 μL DMEM. Five days post transduction, mice were infected 532 intranasally with SARS-CoV-2 (1 × 10 5 PFU) in a total volume of 50μL DMEM. 533 Vero E6 cells were seeded in 96-well plates one day before infection. Tissue 535 homogenates were serially diluted and used to inoculate Vero E6 cells at 37℃ for 1 h. 536 Inoculate were then removed before adding 125 μL 1.6% carboxymethylcellulose per well and warmed to 37℃. After 24 h, cells were fixed with 4% paraformaldehyde and 538 permeabilized with 0.2% Triton X-100. Cells were then incubated with a rabbit anti-539 SARS-CoV-2 nucleocapsid protein polyclonal antibody (Cat. No.: 40143-T62, Sino 540 Biological), followed by an HRP-labeled goat anti-rabbit secondary antibody (Cat. 541 No.: 109-035-088, Jackson Immuno Research Laboratories). The foci were visualized 542 by TrueBlue Peroxidase Substrate (KPL) and counted with an ELISPOT reader 543 (Cellular Technology). Viral titers were calculated as per gram tissue. 544 L2 cells were grown in 60-mm dishes to 70-80% confluence and infected with 546 1 mL of media containing viruses at dilutions ranging from 10-3 to 10-6. After 1 h at 547 37℃, the inoculate were removed. Seven ml of 0.95% agar (Amresco) in DMEM 548 with 5% FBS was overlaid onto cells at 1-2h. Plaques were picked between 24 and 549 36 h. For plaque staining, 3 mL of agar containing 0.02% neutral red (Sigma-Aldrich) 550 was overlaid onto cells. Six to eight hours later, the stained plaques were counted. 551 Blood was incubated at room temperature to allow coagulation and was then 553 centrifuged to obtain serum; the serum was used for measurements of alanine 554 transaminase (ALT) and aspartate aminotransferase (AST) levels using Assay Kit 555 (Nanjing Jiancheng Bioengineering Institute). 556 Mice lung, liver and spleen dissections were fixed in zinc formalin and embedded 558 with paraffin. Tissue sections (~4 μm) were stained with hematoxylin and eosin. 559 There were four subtypes high-quality SARS-CoV-2 genomes sequences 561 available in Global Initiative on Sharing All Influenza Data (GISIAD) (Shu et al. under the following criteria: 1) complete genome (>29000bp); 2) high coverage (only 564 entries with <1% Ns and <0.05% unique amino acid mutations and no 565 insertion/deletion unless verified by submitter); 3) low coverage excl (exclude entries 566 with >5% NNNs). In total, we collected Alpha (B.1.1.7) (2021.5.1-6.10 Subsequently, we eliminated 50 Ns or ns sequences. After screening, the remaining 570 sequences were 92214, 6341, 13655, 21611 (Table S4) . Virus data collection is derived from International Committee on Taxonomy of 579 Viruses (ICTV) and NCBI, multi-sequence comparisons using mega 6 , and data 580 visualization using texshade (Beitz 2000) (Table S4) Middle East respiratory 608 syndrome coronavirus: transmission and phylogenetic evolution The ProTide Prodrug 611 Technology: Where Next? Aswin Sai Narain Seshasayee. 2021. 613 'SARS-CoV-2 sequence typing, evolution and signatures of 614 selection using CoVa, a Python-based command-line utility Remdesivir for the Treatment of 626 TEXshade: shading and labeling of multiple sequence 628 alignments using LATEX2 epsilon Emerging coronaviruses: Genome 630 structure, replication, and pathogenesis Synthesis and 634 antiviral activity of a series of 1'-substituted 4-aza-7 Repurposed Antiviral Drugs for Covid-19 -655 Interim WHO Solidarity Trial Results 2020. 659 'Druggable targets of SARS-CoV-2 and treatment opportunities 660 for COVID-19 2021. 665 'Molnupiravir, an Oral Antiviral Treatment for COVID-19 Human Coronavirus: Host-Pathogen 668 COVID-19: A Simplified Summary Remdesivir for 5 677 or 10 Days in Patients with Severe Covid-19 AT-681 527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a 682 Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral 683 Antiviral for Treatment of COVID-19 Coronavirus 686 Infections in Companion Animals: Virology Clinical and Pathologic Features', Viruses SARS-CoV-2 variants, spike mutations and 692 immune escape Structure of replicating SARS-CoV-2 polymerase Chemical 697 stability of esters of nicotinic acid intended for pulmonary 698 administration by liquid ventilation 2021. 701 'GS-441524 inhibits African swine fever virus infection in 702 vitro Identification of novel 705 subgenomic RNAs and noncanonical transcription initiation 706 signals of severe acute respiratory syndrome coronavirus Current 709 status on treatment options for feline infectious peritonitis 710 and SARS-CoV-2 positive cats A Convenient and Biosafe Replicon with Accessory 714 Genes of SARS-CoV-2 and Its Potential Application in Antiviral 715 Drug Discovery', Virol Sin Mechanism of 718 molnupiravir-induced SARS-CoV-2 mutagenesis MAFFT: a novel 721 method for rapid multiple sequence alignment based on fast 722 Fourier transform The Architecture of SARS-CoV-2 Transcriptome Mechanism of SARS-CoV-2 polymerase stalling by 729 remdesivir 2020. 731 'Of Mice and Men: The Coronavirus MHV and Mouse Models as a 732 Translational Approach to Understand SARS-CoV-2', Viruses Molecular biology of transmissible 735 gastroenteritis virus Ester bonds in prodrugs Porcine epidemic diarrhea virus: An emerging and re-739 emerging epizootic swine virus Inhibits SARS-CoV-2 Infection in Mouse Models' Reduced neutralization of SARS-CoV-2 B.1.617 758 by vaccine and convalescent serum GS-5734 and 763 its parent nucleoside analog inhibit Filo-, Pneumo-, and 764 Paramyxoviruses Prodrugs 771 of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to 772 the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of 773 Monkey Model of RSV' Global Genomic Analysis of SARS-781 CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug 782 Microorganisms A bioavailability score' SARS-CoV-2 immune 792 evasion by variant B.1.427/B.1.429', bioRxiv Pharmacological activation of STING blocks 799 SARS-CoV-2 infection Consortium Genotype to Phenotype Japan SARS-CoV-2 806 spike L452R variant evades cellular immunity and increases 807 infectivity The 810 nucleoside analog GS-441524 strongly inhibits feline infectious 811 peritonitis (FIP) virus in tissue culture and experimental cat 812 infection studies GS-441524 Studies Lethality of SARS-CoV-2 infection in K18 human angiotensin-827 converting enzyme 2 transgenic mice Efficacy and safety of the 830 nucleoside analog GS-441524 for treatment of cats with 831 naturally occurring feline infectious peritonitis Coronaviruses post-SARS: update 834 on replication and pathogenesis 2020. 836 'Targeting the RdRp of Emerging RNA Viruses: The Structure-837 Based Drug Design Challenge CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the 846 SARS-CoV-2 RNA Polymerase in Mice How the Delta variant achieves its ultrafast 848 spread Molecular Basis and Therapeutic Targeting Updated Review on SARS-CoV-2 Main Proteinase (M(Pro)): Protein 855 Structural 858 Evaluation of the Spike Glycoprotein Variants on SARS Transmission and Immune Evasion GISAID: Global initiative on sharing 861 all influenza data -from vision to reality 869 'Generation of a Broadly Useful Model for COVID-19 A Mouse Model of SARS-CoV-2 Infection Detection of a SARS-CoV-2 variant of concern 889 in South Africa The Delta 895 SARS-CoV-2 variant has a higher viral load than the Beta and 896 the historical variants in nasopharyngeal samples from newly 897 diagnosed COVID-19 patients Improved SARS-CoV-2 M(pro) 902 inhibitors based on feline antiviral drug GC376: Structural 903 enhancements, increased solubility, and micellar studies SARS-CoV-2 infection is 911 effectively treated and prevented by EIDD-2801' Remdesivir and chloroquine 915 effectively inhibit the recently emerged novel coronavirus 916 (2019-nCoV) in vitro Structural Basis for 921 RNA Replication by the SARS-CoV-2 Polymerase Transmission, viral kinetics and clinical 928 characteristics of the emergent SARS-CoV-2 Delta VOC in 929 Potency and pharmacokinetics of GS-441524 932 derivatives against SARS-CoV-2' Coronavirus pathogenesis SARS-CoV-2 Variants, Working Definitions and Actions 936 WHO Coronavirus (COVID-19) Dashboard A new coronavirus associated with human 944 respiratory disease in China Structural basis 949 for repurpose and design of nucleoside drugs for treating 950 COVID-19 Structural basis for inhibition (A) Time-plasma concentration curve of the nucleoside following single IV (4mg/kg) 988 or IG (20 mg/kg) administration of ATV006 to SD rats (n = 3, Mean ± SD). (B) Plasma 989 concentration of the nucleoside following single IV (5 mg/kg) or IG (10 mg/kg) 990 administration to cynomolgus monkeys (n = 3, Mean ± SD). (C) Tissue distribution of 991 the parent nucleoside followed a single oral dose of 100 mg/kg ATV006 to C57BL/6 992 mice (n = 5, Mean ± SD). 993 Table S3 . The black triangles represent the key sites where remdesivir binds to RdRp. The red 1081 triangles represent the enzyme activity amino acid residues of RdRp. The red dots 1082 represent the amino acid sites whose mutation rate is greater than one percent and less 1083 than eighty percent compared with the original strain. The blue dots represent the amino 1084 acid sites whose mutation rate is greater than eighty percent compared with the original 1085 strain. 1086